前期研究表明血小板衍生生长因子-BB (platelet-derived growth factor-BB, PDGF-BB)与冠心病关系密切, 本文基于表面增强拉曼光谱(surface-enhanced Raman spectroscopy, SERS)方法, 结合PDGF-BB拉曼频移为1 509 cm-1的拉曼特征峰, 对60例冠心病患者, 其中包括20例行皮冠状动脉介入治疗术(percutaneous coronary intervention, PCI)病人与40例未行PCI病人的尿液样本以及18例健康人尿液样本进行分析。结果显示: 行PCI病人的尿液样本SERS光谱中可以检测到1 509 cm-1 的拉曼特征峰; 而在健康人与大多数未行PCI病人的尿液SERS光谱中则检测不到。与临床资料对比发现, 尿液SERS光谱与冠状动脉造影技术在判断心血管堵塞程度是否达到70%以上吻合度较高。基于表面增强拉曼光谱的冠心病检测方法有望发展为一种无创的冠心病前瞻性诊断工具, 对于冠心病疑似病例是否需要行PCI提供可靠的临床诊断依据。

In the previous research, it was found that Platelet-derived growth factor-BB (PDGF-BB) was closely related to coronary heart disease. Here, 60 urine samples from patients with coronary heart disease including 20 patients with PCI (percutaneous coronary intervention) and 40 patients without PCI and 18 urine samples from healthy human were investigated based on surface-enhanced Raman spectroscopy (SERS). It revealed that the peak at 1 509 cm-1 attributing to PDGF-BB could be detected in the urine samples from the patients with PCI and cannot be detected in the urine samples from healthy human and most of patients without PCI. Compared with the clinical data, it was shown that the SERS spectra of urine samples were in good agreement with the results of coronary angiograph technology in determining whether cardiovascular congestion was above 70%. The measurement of human urine based on SERS could be developed as a noninvasive and prospective diagnostic tool for coronary heart disease, and it provided viable clinic information for judging the suspected cases of coronary heart disease and deciding whether performing PCI.